Baidu
map

Oncotarget:COL3A1过表达或与膀胱癌预后差相关。

2017-10-27 fengxiangxin MedSci原创

在此研究中,研究者构建了加权基因共表达网络,以鉴定与BCa(n = 93)进展相关的基因模块。在重要模块(R(2)= 0.48)中,共鉴定出103个网络hub基因,其中4个同时是蛋白质 - 蛋白质相互作用网络中的中枢节点。

膀胱癌(BCa)是世界范围内男性和女性中高发的癌症之一,其病因和机制尚不清楚。

在此研究中,研究者构建了加权基因共表达网络,以鉴定与BCa(n = 93)进展相关的基因模块。在重要模块(R(2)= 0.48)中,共鉴定出103个网络hub基因,其中4个同时是蛋白质 - 蛋白质相互作用网络中的中枢节点。

在验证中发现,与测试组hub模块中的任何其他hub基因相比,COL3A1显示出与疾病进展更高的相关性(p <0.001)。基因功能和通路富集分析表明,COL3A1在焦点黏连通路中过表达,这与肿瘤进展相关并可能导致肿瘤转移。基因组富集分析(GSEA)也表明,COL3A1高度表达的BCa样品中富集了“MAPK信号通路”基因集和焦点粘附相关通路(FDR <0.05)。

联系临床病理参数发现:COL3A1高表达与局部复发和BCa分期密切相关。生存分析显示,COL3A1表达较高的BCa患者的总生存时间和无病生存时间均明显缩短。

总之,基于共表达分析,鉴定出COL3A1与BCa进展和预后相关。它对MAPK信号通路的调节可能与不良预后相关。

原始出处:

Yuan L, Shu B, Chen L.et al.Overexpression of COL3A1 confers a poor prognosis in human bladder cancer identified by co-expression analysis.Oncotarget. 2017 Jul 28;8(41):70508-70520. doi: 10.18632/oncotarget.19733. eCollection 2017 Sep 19.

本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795480, encodeId=f98a1e9548020, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Jul 26 21:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783277, encodeId=5ed31e83277fe, content=<a href='/topic/show?id=5fb44986ab' target=_blank style='color:#2F92EE;'>#COL3A1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4986, encryptionId=5fb44986ab, topicName=COL3A1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Aug 18 04:27:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958168, encodeId=895e1958168db, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Nov 14 09:27:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256952, encodeId=5cd8256952b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Oct 29 12:50:54 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256559, encodeId=ae672565597f, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Oct 28 07:02:09 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256445, encodeId=59b72564459c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:51:40 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2018-07-26 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1795480, encodeId=f98a1e9548020, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Jul 26 21:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783277, encodeId=5ed31e83277fe, content=<a href='/topic/show?id=5fb44986ab' target=_blank style='color:#2F92EE;'>#COL3A1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4986, encryptionId=5fb44986ab, topicName=COL3A1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Aug 18 04:27:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958168, encodeId=895e1958168db, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Nov 14 09:27:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256952, encodeId=5cd8256952b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Oct 29 12:50:54 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256559, encodeId=ae672565597f, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Oct 28 07:02:09 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256445, encodeId=59b72564459c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:51:40 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1795480, encodeId=f98a1e9548020, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Jul 26 21:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783277, encodeId=5ed31e83277fe, content=<a href='/topic/show?id=5fb44986ab' target=_blank style='color:#2F92EE;'>#COL3A1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4986, encryptionId=5fb44986ab, topicName=COL3A1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Aug 18 04:27:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958168, encodeId=895e1958168db, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Nov 14 09:27:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256952, encodeId=5cd8256952b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Oct 29 12:50:54 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256559, encodeId=ae672565597f, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Oct 28 07:02:09 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256445, encodeId=59b72564459c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:51:40 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2017-11-14 lq1767
  4. [GetPortalCommentsPageByObjectIdResponse(id=1795480, encodeId=f98a1e9548020, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Jul 26 21:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783277, encodeId=5ed31e83277fe, content=<a href='/topic/show?id=5fb44986ab' target=_blank style='color:#2F92EE;'>#COL3A1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4986, encryptionId=5fb44986ab, topicName=COL3A1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Aug 18 04:27:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958168, encodeId=895e1958168db, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Nov 14 09:27:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256952, encodeId=5cd8256952b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Oct 29 12:50:54 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256559, encodeId=ae672565597f, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Oct 28 07:02:09 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256445, encodeId=59b72564459c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:51:40 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2017-10-29 大爰

    学习了谢谢分享!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1795480, encodeId=f98a1e9548020, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Jul 26 21:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783277, encodeId=5ed31e83277fe, content=<a href='/topic/show?id=5fb44986ab' target=_blank style='color:#2F92EE;'>#COL3A1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4986, encryptionId=5fb44986ab, topicName=COL3A1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Aug 18 04:27:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958168, encodeId=895e1958168db, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Nov 14 09:27:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256952, encodeId=5cd8256952b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Oct 29 12:50:54 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256559, encodeId=ae672565597f, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Oct 28 07:02:09 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256445, encodeId=59b72564459c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:51:40 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2017-10-28 thlabcde

    好资料学习了!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1795480, encodeId=f98a1e9548020, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Jul 26 21:27:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783277, encodeId=5ed31e83277fe, content=<a href='/topic/show?id=5fb44986ab' target=_blank style='color:#2F92EE;'>#COL3A1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4986, encryptionId=5fb44986ab, topicName=COL3A1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Aug 18 04:27:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958168, encodeId=895e1958168db, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Tue Nov 14 09:27:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256952, encodeId=5cd8256952b2, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Oct 29 12:50:54 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256559, encodeId=ae672565597f, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sat Oct 28 07:02:09 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256445, encodeId=59b72564459c, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Oct 27 18:51:40 CST 2017, time=2017-10-27, status=1, ipAttribution=)]
    2017-10-27 131****1460

    学习了受益匪浅

    0

相关资讯

Sci Rep:血液淋巴细胞染色体异常或可预测膀胱尿路上皮和鳞状细胞癌风险。

血液淋巴细胞中的染色体畸变(CA)已证实与整体癌症风险和老化有关。然而,他们与膀胱癌风险之间的关系尚待阐明。

Eur Urol:预测患者对膀胱内灌注卡介苗免疫治疗的反应

卡介苗(BCG)是目前治疗非侵入性膀胱癌最有效的膀胱内疗法,不仅可以减少复发率,而且可以预防疾病进展和减少死亡。然而,患者对BCG的反应差异很大,并且这取决于诸多因素。

Biomaterials:PLZ4-纳米卟啉可有效用于膀胱癌的治疗

膀胱癌的总体预后在过去30年并没有改善,因此,亟需找到膀胱癌新型诊断和治疗方法。本研究中,研究人员开发了一种多功能纳米卟啉平台,其中涂有膀胱癌特异性配体PLZ4。 单一程序中,PLZ4-纳米卟啉(PNP)可整合光动力学诊断、图像引导光动力学治疗、光热疗法和靶向化疗。PNPs是球形的,相对较小(直径约23nm),近红外光照射时优先发射荧光/热/活性氧。与游离DOX相比,PNPs负载多柔比星(DOX)

J Gene Med:通过靶标基因表达传递的膀胱癌非侵入型检测

由于与检测程序相关的时间耗费和对贫穷病人造成的经济压力,膀胱经检查或者是其他的成像技术在症状表现出来之前不可能用于膀胱癌的检测。作为一种选择,泌尿系肿瘤标记的商业化分析是存在的,但是受限于低灵敏度和高花费。因此,简单的并且是敏感的肿瘤检测方法是需要的,比如通过对尿液的分析。质粒在cmv、cox2或者是opn启动子的控制下可编码分泌性报告因子荧光素酶(G.LUC)。研究人员通过聚乙烯亚胺将这些报告系

Oncotarget:膀胱癌侵袭的蛋白质组学分析:靶向EIF3D进行治疗干预。

此研究重点分析了膀胱癌发生侵袭的蛋白质组学变化,旨在更好地了解疾病病理生理学和对药物靶标的鉴定。研究者通过高离析液相色谱联合串联质谱对非肌层浸润性膀胱癌(NMIBC,pTa期)和肌层浸润性膀胱癌(MIBC,阶pT2 +期)患者的组织标本进行了分析。

Indian J Urol:MicroRNA-21可作为预测非肌肉侵入性膀胱癌复发的分子标记

非肌肉侵入性膀胱癌(NMIBC)的高复发率到目前为止还是一个巨大的挑战。 microRNA-21(miR-21)的超表达在膀胱肿瘤组织和正常粘膜的比较已经有所报道,并且miR-21能以与恶性肿瘤相关的磷酸酶和张力蛋白同源体基因(PTEN)为靶标。最近,有研究人员测试了是否miR-21在膀胱粘膜中的水平可以预测肿瘤复发。在一个前瞻性的群体研究中,研究人员在经尿道膀胱肿瘤切除术中从BC病人中获取了肿瘤

Baidu
map
Baidu
map
Baidu
map